Vivanta Tablet contains a fixed-dose combination of Sacubitril 24 mg and Valsartan 26 mg, used for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). This combination belongs to a newer class of medicines known as angiotensin receptor–neprilysin inhibitors (ARNIs). Vivanta Tablet helps improve heart function, reduce hospitalizations due to heart failure, and lower the risk of cardiovascular-related mortality when used as part of a comprehensive heart failure management plan.

Mechanism of Action

Sacubitril works by inhibiting the enzyme neprilysin, which is responsible for the breakdown of beneficial natriuretic peptides. By blocking neprilysin, Sacubitril increases levels of these peptides, leading to vasodilation, increased sodium excretion, and reduced cardiac workload. Valsartan is an angiotensin II receptor blocker (ARB) that prevents the harmful effects of angiotensin II, such as vasoconstriction and fluid retention. Together, these actions improve cardiac efficiency and reduce stress on the heart.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Vivanta Tablet 24 mg + 26 mg is indicated for:

• Treatment of chronic heart failure with reduced ejection fraction

• Patients with symptomatic heart failure to reduce the risk of hospitalization

• Use as a replacement for ACE inhibitors or other ARBs, as prescribed by a physician

• Management of heart failure as part of combination therapy with other standard heart failure medicines

Dosage and Administration

The dosage of Vivanta Tablet should be determined by the treating physician based on the patient’s clinical condition, prior therapy, and tolerance. It is typically taken twice daily, with or without food. Tablets should be swallowed whole with water. Dose adjustments may be required during treatment, and regular monitoring of blood pressure, kidney function, and potassium levels is recommended.

Benefits

• Improves heart function and symptoms of heart failure

• Reduces the risk of hospitalization due to worsening heart failure

• Lowers cardiovascular mortality in patients with HFrEF

• Helps improve quality of life and exercise tolerance

• Convenient fixed-dose combination enhances treatment adherence

Possible Side Effects

Vivanta Tablet is generally well tolerated, but some patients may experience:

• Low blood pressure (hypotension)

• Dizziness or lightheadedness

• Increased blood potassium levels

• Kidney function changes

Serious side effects such as angioedema are rare but require immediate medical attention.

Precautions and Warnings

• Should not be used with ACE inhibitors; a washout period is required before starting therapy

• Use with caution in patients with kidney impairment or low blood pressure

• Not recommended during pregnancy due to risk to the fetus

• Breastfeeding should be discussed with a healthcare provider

• Regular monitoring is important to ensure safe and effective use

Drug Interactions

Vivanta Tablet may interact with potassium supplements, potassium-sparing diuretics, other blood pressure–lowering medicines, and certain NSAIDs. Patients should inform their healthcare provider about all medicines they are taking.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

Store Vivanta Tablet 24 mg + 26 mg in a cool, dry place away from direct sunlight. Keep out of reach of children.

Conclusion

Vivanta Tablet 24 mg + 26 mg (Sacubitril + Valsartan) is an advanced and effective treatment option for patients with chronic heart failure with reduced ejection fraction. When used under medical supervision and combined with lifestyle modifications and standard therapy, it plays a vital role in improving heart function, reducing hospitalizations, and enhancing long-term cardiovascular outcomes.